Aptar Pharma secures CE marking for LuerVax intranasal vaccine device

LuerVax intranasal device receives CE marking under EU MDR. Approval enables use in European vaccine clinical studies and commercialization. Spray Divider supports two sequential sprays using 200 µL or 500 µL volumes. Integrated services include regulatory support and manufacturing expertise.

AptarGroup Russian subsidiary placed under temporary external administration

OOO Aptar Vladimir placed under temporary external administration by Russian presidential decree on September 21, 2026. Subsidiary represented less than 0.6% of consolidated net sales and operating income as of December 31, 2025. Unit accounted for less than 1% of AptarGroup's consolidated assets at year-end 2025. Company is assessing options and committed to protecting its rights.

AptarGroup signs MGH deal to advance nose-to-brain drug delivery science

AptarGroup signs research collaboration with Massachusetts General Hospital. Partnership aims to develop predictive model for nose-to-brain drug delivery. Goal is to help innovators evaluate CNS pipeline opportunities earlier.

AptarGroup Q2 2026 Results: Sales Cross $1 Billion, Adj. EPS Beats at $1.42

AptarGroup reported second quarter 2026 results with net sales of $1.03 billion, up 6% YoY and crossing $1 billion for the first time, while adjusted EPS of $1.42 beat analyst estimates of $1.35 but declined from the prior year's $1.68. All three segments—Pharma, Beauty, and Closures—delivered reported sales growth, though adjusted EBITDA margin compressed to 20.7% from 22.6%. For the six months ended June 30, 2026, reported sales rose 8% to $2.01 billion and adjusted EPS was $2.61, down 12% year-over-year. The company guided Q3 2026 adjusted EPS to $1.45–$1.53 and returned $212 million year-to-date to shareholders.

AptarGroup Q3 Results: Adj EPS guidance beats estimates

AptarGroup projects Q3 adjusted EPS of $1.45-$1.53, beating the $1.46 analyst estimate. The guidance highlights expected profitability strength, with the upper end of the range offering significant upside over consensus views.

Aptar Beauty launches NeoDropper Autoload for precision dosing

Aptar Beauty introduces the NeoDropper Autoload, an auto-loading dropper technology for precision skincare dosing, now featured on Dermalogica's FutureCode Booster serum. The innovation aims to improve hygiene, dosage control, and reduce waste, aligning with the rising demand for clinically validated skincare products. This launch strengthens Aptar's collaboration with Dermalogica, following their 2022 partnership on a fully recyclable dispensing pump.